april 30reuter us food drug administr thursday approv sale breo ellipta oncedaili treatment asthma patient age 18 older glaxosmithklin therav inc said fda declin approv breo younger asthma suffer agenc socal complet respons letter told compani addit data would requir demonstr breo safeti efficaci populationth fdas decis came fda advisori panel expert vote 164 breo ellipta approv use adult vote 191 avail data support approv use children age 12 17 breo ellipta use relief acut bronchospasm compani saidbernstein analyst tim anderson forecast breo sale reach 750 million drug consist corticosteroid reduc inflamm longact betaagonist call vilanterol design open airwaysglaxo licens drug therav 2002 inhal treatment previous approv treat chronic obstruct pulmonari diseas copd condit includ emphysema chronic bronchiti report bybil berkrotin new york edit leslieadl 